Jul. 23, 2021 11:11 AM ET By: Jonathan M Block, SA News Editor
Immix Biopharma has confidentially submitted a draft registration statement (S-1 form) for an initial public offering.
The number of shares to be offered and the share price range have yet to be determined.
Immix’s SMARxT Tissue-Specific Platform oncology drug candidates use the company’s TME Normalization Technology, which allows the therapies to circulate in the bloodstream, then exit through porous tumor blood vessels, accumulating in the tumor micro-environment.
Its latest stage asset, MX-110, is in phase 1b/2a for soft tissue sarcoma.